Alterity Therapeutics-ADRATHE
13F holders, Q4 2025 (December 31)18holders +2
4new positions
2sold out
1famous investor
$3.08avg. 13F price*
At the end of Q4 2025, 18 institutions reported holding Alterity Therapeutics-ADR (ATHE) in their 13F filings, up 2 from Q3 2025. 4 opened new positions and 2 sold out. The largest holders were Twin Lakes Capital Management, LLC ($429K), Morgan Stanley ($196K) and HB Wealth Management, LLC ($180K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Alterity Therapeutics-ADR
- CUSIP
- 02155X205
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $3K |
| Exits | 2 | $670 |
All 13F filers, Q3 2025 → Q4 2025: 2,102 shares bought and 11,646 shares sold, net −9,544 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| Twin Lakes Capital Management, LLC | 0.19% | No change | 139,258 | $429K |
| Morgan Stanley | 0.00% | Reduce -7.3% | 63,682 | $196K |
| HB Wealth Management, LLC | 0.00% | No change | 58,460 | $180K |
| Greenleaf Trust | 0.00% | No change | 32,000 | $99K |
| Citadel Advisors | 0.00% | Reduce -24.1% | 16,811 | $52K |
| BNP Paribas Financial Markets | 0.00% | Reduce -5.5% | 6,909 | $21K |
| Acadian Asset Management LLC | 0.00% | No change | 4,799 | $14K |
| Rhumbline Advisers | 0.00% | Add +140.1% | 2,127 | $7K |
| GAMMA Investing LLC | 0.00% | New | 790 | $2K |
| Osaic Holdings, Inc. | 0.00% | Reduce -55.3% | 81 | $247 |
| Blue Trust, Inc. | 0.00% | No change | 40 | $123 |
| Farther Finance Advisors, LLC | 0.00% | No change | 22 | $68 |
| CoreCap Advisors, LLC | 0.00% | New | 21 | $65 |
| Tower Research Capital LLC (TRC) | 0.00% | New | 10 | $31 |
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 6 | $18 |
| Danske Bank A/S | 0.00% | No change | 1 | $3 |
| Citigroup Inc. | 0.00% | Reduce -99.8% | 1 | $3 |
| Motiv8 Investments LLC | 0.00% | New | 40 | $0 |
"% of holder's portfolio" is ATHE's weight in each manager's 13F, not the share of Alterity Therapeutics-ADR the manager owns.